Knowledge Hub

Global Lung Cancer Therapeutics Market To Contribute Around $11.19 Billion During The Period 2016-2020

Press release   •   Nov 25, 2016 05:06 EST has recently announced the addition of a market study “ Global Lung Cancer Therapeutics Market 2016-2020 ”, is a comparative analysis of the global market.

About Lung Cancer Therapeutics

Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavios analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:




Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Download The sample Copy Of This Report:

Key vendors

F. Hofmann-La Roche

Eli Lilly




Other prominent vendors






ARIAD Pharmaceuticals

Astellas Pharma

Betta Pharmaceuticals

BeyondSpring Pharmaceuticals

BioNumerik Pharmaceuticals

Boehringer Ingelheim

Boston Biomedical

Bristol-Myers Squibb


CTI BioPharma





Hutchison Medipharma

Ionis Pharmaceuticals

Kadmon Corporation




NovaRx Corporation


Ono Pharmaceutical

OSE Immunotherapeutics

OSI Pharmaceuticals



Pierre Fabre



Samsung Bioepis


SFJ Pharmaceuticals

Spectrum Pharmaceuticals

Sumitomo Dainippon Pharma


Takeda Pharmaceuticals

Teva Pharmaceutical


Market driver

Growing demand for targeted therapies

For a full, detailed list, view our report

Market challenge

Growing popularity of alternative therapeutics

For a full, detailed list, view our report

Market trend

Emergence of nanomedicine platform for the treatment of lung cancer

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Table Of Content

PART 01: Executive summary


PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Economic burden

Types of lung cancer


Staging of SCLC

Staging of NSCLC

Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

Global lung cancer therapeutics market

Five forces analysis

PART 08: Market segmentation by disease type


Global NSCLC market overview


Global SCLC market overview

PART 09: Market segmentation by type of molecule

Small molecules


PART 10: Geographical segmentation

Lung cancer therapeutics market in Americas

Lung cancer therapeutics market in EMEA

Lung cancer therapeutics market in APAC

PART 11: Market drivers

Growing demand for targeted therapies

Presence of blockbuster drugs coupled with longer patent exclusivities

Advancements in identification of molecular biomarkers increasing patient pool

Paradigm shifts toward the adoption of checkpoint inhibitors